At the committee’s recommendation, the primary endpoint is changed to “alive and free of respiratory failure at 7-10 days.” This change in primary endpoint from mortality at 28 days is driven by the general decrease in mortality with advances in treatment for Critical COVID-19 and by initial observations in the clinical trial.



Read More: https://investorshangout.com/post/view?id=584...z6UDhhzGpI

Wouldn't a similar change in our phase 3 endpoint also highlight leronlimab's ability to calm the chemokine storm in our stage 2- m/m trial thereby preventing lung and liver damages?
What do you think Ohms?